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p53 is an important tumor suppressor gene which is activated in response to DNA damage. The induced expression of p53 causes either cell cycle G1 arrest or apoptosis. The recently cloned p21 gene (WAF1/ CIP1/SDI1) is known to be directly activated by wild-type but not mutant p53 and can suppress the growth of human cells in G1 by inhibiting the activity of cyclin-dependent kinases (CDKs). As p21 is activated by p53 and is a negative regulator of the cell cycle, it is possible that p21 could be a sensitive marker to monitor p53 function. To investigate the mRNA expression level and mutation status of p53 and p21 genes, quantitative polymerase chain reaction (PCR) and direct cDNA sequence analysis were performed. mRNA expression levels of p53 and p21 genes relative to the b-tubulin gene were examined in 32 ovarian tumors (24 carcinomas, six low malignant potentials (LMPs), two benigns) and six normal ovaries. Of 13 ovarian tumors with p21 underexpression, nine p53 mutated cases (69%) and one polymorphism case were found. Among nine p53 mutated cases, three cases showed p53 overexpression, another three cases showed p53 underexpression and a further three cases showed normal expression of p53. These findings suggest that mRNA underexpression of p21 may be a more useful indicator of p53 dysfunction than mRNA expression of p53.
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Ovarian cancer is the fourth most common cause of female cancer death and the most common cause of death from gynecologic cancer (1) . As ovarian cancer is often asymptomatic in its early stages, a majority of the patients are diagnosed at an advanced clinical stage despite recent advances in imaging technology and the availability of assay systems for serum tumor markers (2) . It therefore remains necessary to develop new diagnostic markers for screening women at risk for ovarian cancer.
Even though the genetic alterations involved in ovarian carcinoma remain largely unknown, as is the case with other common human carcinomas, a series of multiple genetic defects are believed to be involved in the development of ovarian cancer (3) . Some genetic abnormalities can alter the normal function of cancerrelated gene products quantitatively and/or qualitatively, thereby it is necessary to evaluate over/underexpression as well as mutation in the carcinogenic process (4) . Currently established prognostic factors for ovarian cancer, including clinical stage, histologic type and histological grade, provide a framework for the selection of appropriate treatment. However, there remains the need to catalog the genetic insults relative to both prognosis and treatment response so that therapy can be individualized and directed toward control of the biologic aberrations. p53 is activated in response to DNA damage and the induced expression of p53 causes either cell cycle G1 arrest or apoptosis (5±7) . This blockade of DNA synthesis prevents the accumulation of mutations that could contribute to the development of neoplastic cells. p21 (WAF1/CIP1/SDI1), which encodes an inhibitor of cyclin-dependent protein kinase, could explain at least some of the mechanism by which elevated levels of the normal p53 can block cell growth and differentation. p21 (WAF1/CIP1/SDI1) (8±11) is directly activated by wild-type but not human mutant-type p53 and can suppress the growth of human cells by inhibiting the activity of cyclin-dependent kinases (CDKs), which are required for the G1 to S transition of the cell cycle. As p21 is a negative regulator of the cell cycle, it is possible that p21 itself can act as a tumor suppressor gene. It has been reported that mutations within the coding portion of the p21 gene were undetectable in a large series of human tumors and that p21 alterations in expression might be caused through p53 mutation rather than through intragenic mutations of the p21 gene itself (12) . These findings suggest that p21 could be a sensitive marker to monitor p53 dysfunction. In the present study, we attempted to determine the relationship between mRNA expression of the p53 and p21 genes and the mutational status of the p53 gene in ovarian tumors. The expression level of each gene was determined by using a quantitative polymerase chain reaction (PCR) technique and mutation analysis was performed by direct cDNA sequencing.
Patients and methods

Tissue samples
Fresh surgical specimens of ovarian epithelial tumors were obtained from 32 patients. They consisted of two benign cystadenomas, six cystadenomas of low malignant potential (LMP) and 24 cystadenocarcinomas. Clinical staging was determined according to the criteria of FIGO. Normal ovaries were obtained from six patients who underwent surgery for benign gynecological disease. The materials were collected immediately after the surgical procedure were frozen in liquid nitrogen and stored at 7808C. mRNA isolation mRNA was prepared by using a RioSep mRNA Isolation Kit (Becton Dickinson Labware). 0.5±1.0 g of tissue samples were ground in a mortar and pestle under liquid nitrogen. Ten ml of lysis buffer and 2 mg of proteinase-K were added and the slurry was homogenized for 30 s. The tissue lysate was incubated for 2 h at 458C. 600 ml of 5M NaCl was added to adjust the NaCl concentration. Ten ml of tissue lysate was added to an oligo (dT) cellulose tube containing 1 ml of binding buffer and this tube was incubated for 1 h. Oligo (dT) cellulose was pelleted by centrifugation and washed with 5 ml of binding buffer several times. Washed oligo (dT) cellulose was transferred to a column and mRNA was eluted with elution buffer. The amount of mRNA recovered was measured by UV spectrophotometry.
cDNA synthesis
Complementary DNA was synthesized using a first strand cDNA synthesis kit (CLONTECH). The cDNA synthesis reaction was performed with 5.0 mmol of dNTPs, 5 mg of mRNA and 20 pmole of random hexmer primer in 20 ml of a solution containing 50 mM tris-HCl (pH 8.3), 75 mM HCl, 3 mM MgCl 2 , 500 mM each dNTP, one unit of RNase inhibitor and 200 units of Moloney-Murine Leukemia Virus reverse transcriptase. After 4 h of incubation at 428C, the reaction was heated to 948C for 5 min to stop cDNA synthesis and cDNA was diluted to a final volume of 100 ml. The efficiency of the cDNA synthesis was estimated by using G3PDH (glyceraldehyde-3 phosphate dehydrogenase) as a positive control amplimer (CLONTECH).
Quantitative PCR
Quantitative PCR was performed according to the method of Noonan et al. (13) with some modification. Polymerase chain reaction was carried out in a Thermal Cycler (Perkin-Elmer Cetus) with the mixture consisting of cDNA derived from 50 ng of mRNA, 5 pmol of sense and antisense primers for both the target gene and the b-tubulin gene, 200 mmol of dNTPs, 5 mCi of [a-32 P] dCTP and 0.25 units of Taq DNA polymerase with reaction buffer (Promega) in a final volume of 25 ml. The primer sequences used for quantitative PCR are listed in Table 1 . Pairs of the primers were designed to include intron sequences as a monitor of genomic p21 underexpression indicates p53 dysfunction 297 DNA contamination in the PCR mix. The primer sequences used in this study were designed according to the cDNA sequences described by Lamb et al.
(p53) (14) , El-Deiry et al. (p21) (9) and Hall et al. (btubulin) (15) . The target sequences were amplified in parallel with the b-tubulin gene as an internal control. Each cycle of PCR included 30 s of denaturation at 958C, 1 min of primer annealing at 628C and 1 min of extension at 728C. Thirty cycles of PCR were performed. The products were separated on 2% agarose gel and the radioactivity of each band was determined by a Phospho-Imager (Molecular Dynamics). The statistical significance of the correlation between p21 underexpression and p53 mutation was examined using the w 2 test.
Direct cDNA sequencing
Polymerase chain reaction was carried out with the amplification primers described in Table 2 . p53 cDNA was sequenced from codon 7 to codon 351 extending from the middle of exon 2 to the middle of exon 10. Amplified cDNA samples were purified using the Wizard PCR DNA Purification System (Promega). The sequencing reaction was carried out using Prism ReadyReaction Dyre Deoxy Terminators, the completed sequencing reaction was purified using a Centri-Sep Spin Column (Princeton Separations). The Applied Biosystems Model 373A DNA Sequencing System was used for direct cDNA sequence determination.
Immunohistochemistry
Immunohistochemical staining was performed using a VECTASTAIN Elite ABC kit (Vector). Formalin fixed and paraffin embedded specimens were routinely deparaffinized and processed using microwave heat treatment in 0.01 M sodium citrate buffer (pH 6). The specimens were incubated in methanol with 0.3% H 2 O 2 for 30 min at room temperature, the samples were incubated with anti-p53 protein monoclonal antibody (IMMUNOTECH) for 1 h at room temperature in a moisture chamber, followed by incubation with biotinylated anti-mouse IgG (Vector) for 30 min at room temperature, and then incubated with ABC reagent (Vector) for 30 min at room temperature. The final products were visualized by using the AEC Substrate System (DAKO) and sections were counterstained with hematoxylin before mounting. Negative controls were performed by using normal serum instead of the primary antibody.
Results
Quantitative PCR
Since differences in the extent of RNA degradation and purity between different preparations can have a great effect on the yield of PCR products, the target sequence was amplified in parallel with an internal control sequence corresponding to a common mRNA expressed in the same cell. Ideally, the control sequence should be present at similar levels in different types of cells (normal and tumor) and at an abundance comparable to that of target sequence. In our initial study for quantitative PCR, we tested the b-actin gene, the b-tubulin gene and the G3PDH (glyceraldehyde-3 phosphate dehydrogenase) gene as potential internal controls for both p53 and p21 quantitative PCR analysis. The expression levels of bactin gene and G3PDH gene were so dominant compared to those of p53 and p21 genes that both bactin gene and G3PDH gene were deemed as unsuitable for use as an internal control gene in the quantitative PCR (data analysis not shown). We found that the b-tubulin gene expression, however, showed reasonably similar expression levels to that of the p53 and the p21 genes and the expression level of btubulin was consistent in both normal cells and cancer cells. Accordingly, we decided to use the b-tubulin gene as an internal control gene in this study.
In order to determine the number of PCR cycles appropriate for quantitation, PCR was performed from 15 to 35 cycles over five cycle intervals and linearity of the b-tubulin PCR products was monitored using 32 P labelling agarose gels and phosphoimager quantitation of the labelled PCR products. The amplification reaction was measured as the log of 32 P incorporation and was found to be linear over 30 cycles (Fig. 1) . The PCR reaction was also found to be linear when both p53 and b-tubulin primers of p21 and b-tubulin primers were co-amplified (data not shown). All ensuing PCR reactions were therefore carried out for
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K. Shigemasa et al. 30 cycles. The primers used for both quantitative PCR analysis of p21 and p53 and direct cDNA sequencing of p53 are shown in Table 1 and Table 2 , respectively.
p53 expression
Expression levels of p53 mRNA as measured by quantitative PCR were evaluated in six normal, two benign and six LMP tumors and 24 ovarian carcinomas (Fig. 2) . The expression levels of p53 relative to btubulin were higher in seven ovarian cancer cases (29%) and lower in four cancer cases (17%) than that in normal ovaries. p53 levels were also lower in two LMP tumors (33%). Abnormal expression of p53 (either higher or lower) was found in seven out of 17 (41%) serous cystadenocarcinomas and three out of four (75%) mucinous cystadenocarcinomas. These observations are demonstrated in Fig. 3 where underexpression of p53 compared to normal is noted in cases 31 and 36 and overexpression of p53 is noted in Case 33. An aberrant p53 amplification product is also noted in Case 33 (Fig. 3) .
p21 expression p21 expression levels were lower in three LMP tumors (50%) and in 10 ovarian cancer cases (42%) than that of normal ovaries (Fig. 4) . p21 underexpression was found in two out of four stage I±II cases and in eight out of 20 stage III±IV cases (Table 3) . Underexpression of p21 was also found in seven out of 17 serous cystadenocarcinomas and two out of four (50%) mucinous cystadenocarcinomas. Expression of p21 relative to b-tubulin is shown in sion (data not shown). Out of 13 ovarian tumor cases with p21 underexpression, eight cases have aberrant p53 expression (either higher or lower than normal). Abnormal expression of p53 and underexpression of p21 are compared in Table 3 . As noted no abnormal changes were observed in the two benign specimens. In the LMP group p53 underexpression was observed in two of six specimens and p21 underexpression was noted in three of six tumors. For carcinomas, 11 of 24 (46%) showed abnormal p53 expression while 10 of 24 (42%) were shown to underexpress the p21 tumor suppressor gene. For serous cystadenocarcinomas, seven of 17 tumors (41%) demonstrated abnormal p53 expression and seven (41%) were also found to underexpress p21 (Table 3 ).
p53 mutations
All tumors which demonstrated abnormal expression of p53 or underexpression of p21 (a total of 18 cases) were examined for p53 mutations by direct sequencing of the PCR products. Six of the 13 (six of 13) tumors which showed abnormal p53 expression were found to be mutated. For the six mutated cases, three showed underexpression of p53 and three showed overexpression of p53 (Table 4) .
Out of the 13 ovarian tumor cases with underexpression of p21, nine p53 mutations (69%) were found (Fig. 6) . According to the quantitative PCR data, three out of these nine cases showed overexpression of p53, three cases showed underexpression of p53 and three case showed normal p53 expression. Out of five ovarian cancer cases that showed abnormal expression of p53, but did not show underexpression of p21, no p53 mutation was found.
Two cases showed unusual PCR patterns. Case 33 showed two bands instead of one, an unexpected band of 635 bp and the expected band at 285 bp (Figs 3 & 6) . The larger sized product had a G to T transversion at the 3' splicing site of intron-7 that resulted in intron 7 insertion (Table 5 ). The anticipated PCR product of 285 bp was also altered and shown to contain a T to A transversion in codon 206 converting it from a leucine codon to a stop codon. In Case 26 an extra p53 product in addition to the expected sized p53 product was detected (Fig. 6 ). In this case the smaller sized product had a 58 bp deletion from codon 106 to codon 125 which resulted in stop codon at codon 150. The mutations observed in p53 are spread over exons 4 through 7 and all predict an amino acid change in the regulatory domain of the p53 protein ( Table 5 ). As already mentioned we also observed a deletion of amino acids 106 to 125 in Case 26 and an insertion of intron 7 due to a splice site mutation in Case 33 (Table 5 ).
p53 immunohistochemistry
Four normal, one benign and three LMP tumors plus 14 carcinomas were examined for p53 expression by immunostaining. In eight cases with p53 mutation 2+ staining for p53 protein was detected. Increased staining (1+) was also detected in one case with a p53 polymorphism. No increased staining was detected in four normal ovarian or in seven cases with wild-type p53. One LMP case with a p53 polymorphism also showed no increased p53 staining (Table 4 ).
Discussion
The mechanism by which elevated levels of normal p53 can block cell growth and differentiation is beginning to be understood. p53 is activated in response to DNA damage (5) and increases transcription of p21 (9) . p21 complexes with and inhibits the activity of cyclin-CDK complex (8, 10) . Since the cyclin-CDK complex stimulates cell division by adding 300 K. Shigemasa et al. phosphate to the retinoblastoma (Rb) protein and releasing E2F to activate the transition from G1 to S phase (16) , p21 could prevent cells from entering S phase and result in G1 arrest (Fig. 7) . As inactivation of the p53 gene by mutation is the most common genetic mutation in human cancers (17) , these findings provide a link between dysfunction of p53 and tumor cell progression through the dysregulation of the cell cycle. Since ovarian cancer is one of the tumors in which dysfunction of p53 with mutations occurs frequently (18±24) , dysregulation of cell cycle control through the p53-p21 pathway could play a critical role in the spread of some ovarian cancers.
It has been reported that p53 mutations were found in 26±79% of ovarian cancer tissues, and most of the p53 mutations found in ovarian cancer, similar to other human cancers, were missense mutations in the sequence-specific DNA-binding domain (18±24) . In the present study, we found 11 mutations and one polymorphism in nine tumors. Nine of 11 mutations p21 underexpression indicates p53 dysfunction 301 were missense mutations and all 11 mutations were found in the cluster of the sequence-specific DNAbinding domain. These data suggest most of the p53 mutations result in the dysregulation of downstream effectors, such as p21, whose expression is regulated by p53.
It has not been shown whether the mRNA expression level of p53 is reflected by the p53 mutation status. In the present study of nine p53 mutated cases, three cases showed overexpression of p53, another three cases showed underexpression of p53 and the last three cases showed normal p53 expression. These data suggest that p53 mRNA expression level is not a good indicator of p53 mutation status.
Since p21 is directly activated by wild-type p53 protein but not mutant-type p53 protein (9) , downregulation of the p21 mRNA might be expected to occur in the cases with p53 mutation. Our results showed that p21 mRNA expression level was significantly reduced in three LMP tumors and in 10 ovarian cancer cases. Of these 13 ovarian tumor cases with p21 underexpression, nine p53 mutated cases were found (69%) and all nine cases resulted in amino acid changes. These findings suggest that mRNA underexpression of p21 is directly related with p53 dysfunction regardless of the mRNA expression level of p53.
It has been reported that mutant p53 proteins generally have a much longer half-life than wild-type p53 proteins and the extended half-life of p53 protein leads to its accumulation within the nuclei of affected cells (25±26) . Several earlier studies have suggested that immunohistochemical staining of p53 protein is correlated with the presence of p53 missense mutations and it could detect 50±80% of p53 mutated cases in ovarian tumors (18,22±23) However, some kinds of p53 mutation, such as a nonsense mutation or a splicing alteration and most deletions, do not result in the p53 protein accumulation (18) . Furthermore, dysfunction of the p53 protein is not always caused by intra-genic mutations but sometimes caused by several viral and cellular oncoproteins such as the E6 protein (27) Cyclin and CDK stimulate cell division by adding phosphate to the retinoblastoma (Rb) protein and releasing E2F that activates the transition from G1 to S phase. p53 is activated in response to DNA damage and increases transcription of p21. p21 complexes with and inhibits the activity of Cyclin-CDK complex and prevents cells from entering S phase.
human papilloma virus and the p53 binding protein MDM-2 (28±29) . In summary, we have found that nine of 18 tumors with aberrant p53 or p21 expression exhibit at least one p53 mutation. These nine tumors all underexpress p21 mRNA. Four other tumors also underexpress p21, suggesting that p53 dysfunction of p21 underexpression may arise by mechanisms other than p53 mutation; for example, inactivation by endogenous or viral binding proteins or transcriptional activation by pathways independent of p53. The data suggest that p21 mRNA underexpression is a useful indicator of p53 dysfunction and may also reflect p53 independent pathways of p21 expression that result in loss of cell cycle control.
